相关实验视频

Updated: May 2, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

NHHR与肝硬化和肝纤维化之间的关联:基于人口的研究

Xiaoxian Yang¹, Haiyi Yan², Rui Guo²

¹First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.

Scientific reports

|March 12, 2025

概括

非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇的比率 (NHHR) 显示了与非酒精性脂肪肝疾病 (NAFLD) 胆固醇症的U形联系. 保持NHHR低于1.26可能会降低NAFLD风险.

科学领域:

肝病学肝病学是一种肝病学.
心血管医学心血管医学
代谢综合征是代谢综合征的一种.

背景情况:

非酒精性脂肪性肝病 (NAFLD) 是一个日益严重的健康问题,通常与失脂症有关.
非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇的比率 (NHHR) 提供了全面的脂质特征评估.
了解脂质标记物与NAFLD进展的关联对于早期检测和管理至关重要.

研究的目的:

调查NHHR和肝硬化症之间的关系.
检查NHHR和肝纤维化之间的关联.
为了确定与肝脏健康有关的NHHR的潜在值.

主要方法:

使用了2017-2020年国家健康和营养检查调查 (NHANES) 数据集.
从脂质配置文件计算NHHR,并使用振动控制过时弹性学 (VCTE) 评估肝硬化和肝硬度.
使用多重线性回归,平滑曲线和值效应分析来评估关联.

主要成果:

在NHHR和肝肥胖症之间观察到一个U形的关联,在NHHR=1.26.一个显著的断点.
低于1.26的NHHR存在负相关性,高于1.26.的NHHR存在正相关性.
在NHHR和肝纤维化之间没有发现显著的关联.

结论:

NHHR与肝脏肥胖症呈现U形关系,这表明在较低水平时可能存在潜在的保护作用.
保持NHHR低于1.26可能是减轻患肝硬化风险的策略.
在临床实践中,NHHR作为NAFLD监测的高效和成本效益的标志物.

关键词:

肝脏肥胖症肝脏肥胖症肝脏纤维化肝脏纤维化这是NAFLD.尼汉斯 (NHANES) 是一个名人.没有NHHRR.

更多相关视频

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...